ClinicalTrials.gg
RecruitingNCT07700056Updated Nov 9, 2026

A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

A Phase 3 interventional study of Remibrutinib and Placebo in Chronic Pruritus of Unknown Origin, sponsored by Novartis Pharmaceuticals. Recruiting at 24 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 9, 2026First sites in Canada, South Korea and Argentina19 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Pruritus by Novartis — 2 open to participants now, 2 under way, 2 of them phase 3. Pruritus · Novartis.

Planned enrollment
10th of 17
180 · median 182
Started
2026
with 1 other
Phase 3
11 of 17
2 open now
Registered
16th of 17
by date

Among the 17 studies in Pruritus by Novartis, this one is the 10th largest by planned enrollment, is one of 2 that started in 2026, is one of 11 in phase 3, and was the 16th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

2 of the 17 studies in Pruritus by Novartis are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pruritus by Novartis, or all of them as a file.
02

Study summary

The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).

Read the detailed description

This is a global, phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of remibrutinib in adult participants with severe CPUO.

The design includes 4 periods, for a total duration of up to 60 weeks:

  • Screening period: up to 4 weeks.
  • Double-blind treatment period (treatment period 1, TP1): 24 weeks of double-blind treatment with remibrutinib or matching placebo
  • Open-label treatment period (treatment period 2, TP2): 28 weeks of open-label treatment with remibrutinib. The participants randomized to the placebo arm will be switched to remibrutinib at Week 24.
  • Safety follow-up period: 4 weeks of treatment-free safety follow-up.
03

Conditions studied

  • Chronic Pruritus of Unknown Origin

Browse trials for

Keywords

  • BTK inhibitor
  • chronic pruritus
  • chronic pruritus of unknown origin
  • CPUO
  • remibrutinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant must be ≥ 18 years of age, at the time of signing the .
  • Participants with chronic pruritus for at least 4 months prior to screening.
  • Chronic pruritus considered of unknown origin as assessed by the investigator at baseline (e.g., excluding chronic pruritus related to primary dermatological or systemic conditions, neuropathic or psychogenic origin or secondary to drugs or other allergen exposures).
  • Chronic pruritus must affect at least 2 of the following body areas: trunk, arms, or legs (cannot be unilateral and/or dermatomal in distribution).
  • Participants with ongoing, severe chronic pruritus despite the use of emollients and who are candidates for systemic therapy.
  • Participants must have severe itch defined by a WI-NRS ≥7 at screening; score scale ranges from 0 to 10; higher score indicates worse itch.
  • Participants must have an average WI-NRS ≥7 over the 7 days prior to randomization/baseline visit.
  • The average WI-NRS score over the preceding 7 days prior to the randomization/baseline visit will be calculated based on the daily WI-NRS scores (0-10).
  • Participants must have PGIS of pruritus scored as 3 "severe" at screening and baseline visits.

Key Exclusion Criteria:

  • Any active skin conditions (e.g., atopic dermatitis, psoriasis, etc.) that may interfere with the assessment of CPUO.
  • Known systemic condition(s) or medication(s) that are considered by the investigator to be the primary cause of current pruritus.
  • Known or suspected infectious disease that is active, chronic or recurrent which precludes the participant from participating in the clinical trial as per Investigator´s assessment. These infectious diseases include but are not limited to opportunistic infections (e.g., tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis) and/or known or suspected infection.
  • History of of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  • Significant bleeding risk or coagulation disorders. History of gastrointestinal bleeding, e.g., in association with use of nonsteroidal anti-inflammatory drugs (NSAIDs), that was (e.g., where intervention was indicated or requiring hospitalization or blood transfusion). Requirement for anti- medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited.
  • History or current hepatic disease, including but not limited to, acute or chronic hepatitis, cirrhosis or hepatic failure or (AST)/ alanine aminotransferase (ALT) levels of more than 1.5 x (ULN) or (INR) of more than 1.5 at screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Remibrutinib

    Remibrutinib film coated tablets

    Drug: Remibrutinib

  • Experimental
    Placebo followed by remibrutinib

    Matching placebo. At the Week 24 visit, all participants will receive active treatment (remibrutinib).

    Drug: Remibrutinib · Drug: Placebo

Interventions

  • Oral administration of remibrutinib

    Also known as: LOU064

  • DrugPlacebo

    Oral administration of matching placebo.

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving ≥4 point reduction from baseline in Worst itch Numerical Rating Scale (WI NRS)

    The WI-NRS is a patient-reported outcome (PRO) instrument consisting of a single question that asks participants to rate the severity of their worst itch over a defined period. The score range is from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicate worse itch severity.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Proportion of participants achieving ≥4 point reduction from baseline in WI NRS

    The WI-NRS is a PRO instrument consisting of a single question that asks participants to rate the severity of their worst itch over a defined period. The score range is from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicate worse itch severity.

    Time frame: Baseline, Week 4

  2. Proportion of participants achieving Patient Global Impression of Severity (PGIS) score of 0 (none) or 1 (mild)

    The PGIS of pruritus is a PRO measure consisting of a single item that captures the participant's overall self-assessment of the severity of their pruritus (itch) over a defined recall period. The score range is from 0 (none) to 3 (severe). Lower scores indicate better outcome.

    Time frame: Week 12

  3. Proportion of participants achieving Patient Global Impression of Severity (PGIS) score of 0 (none) or 1 (mild)

    The PGIS of pruritus is a PRO measure consisting of a single item that captures the participant's overall self-assessment of the severity of their pruritus (itch) over a defined recall period. The score range is from 0 (none) to 3 (severe). Lower scores indicate better outcome.

    Time frame: Week 24

  4. Change from baseline in Pruritus-related Sleep Disturbance Numerical Rating Scale (SD-NRS)

    The SD-NRS is a PRO instrument used to assess the degree of sleep disturbance caused by pruritus (itch). The score range is from 0 (No sleep disturbance) to 10 (Worst possible sleep disturbance). Higher scores indicate greater sleep disturbance due to pruritus.

    Time frame: Week 12

  5. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants with AEs and SAEs.

    Time frame: Up to Week 52

07

Study locations

24 of 24 sites recruiting
  • Aller Vie Health-Cullman
    Cullman, Alabama 35058, United States
    Recruiting
  • Driven Research
    Miami, Florida 33126, United States
    Recruiting
  • Aeroallergy Research Laboratories
    Savannah, Georgia 31406, United States
    Recruiting
  • Dawes Fretzin Clinical Rea Group
    Indianapolis, Indiana 46256, United States
    Recruiting
    • Joan Prusa · Contactjprusa@ecommunity.com · +1 317 516 5030#102
    • Kenneth Dawes · Principal investigator
  • Southern IN Clinical Trials
    New Albany, Indiana 47150, United States
    Recruiting
  • Equity Medical
    The Bronx, New York 10455, United States
    Recruiting
  • Optima Research-Boardman
    Boardman, Ohio 44512, United States
    Recruiting
  • Allergy and Clinical Immunology Associates
    Pittsburgh, Pennsylvania 15241, United States
    Recruiting
    • Susan Shidel · ContactShidel.sue@gmail.com · +1 412 833 4051
    • Michael Palumbo · Principal investigator
  • National Allergy and Asthma Research LLS
    North Charleston, South Carolina 29420, United States
    Recruiting
  • Austin Inst for Clinical Research
    Pflugerville, Texas 78660, United States
    Recruiting
  • Novartis Investigative Site
    Caba, Buenos Aires C1119ACN, Argentina
    Recruiting
  • Novartis Investigative Site
    Rosario, Santa Fe Province S2000DBS, Argentina
    Recruiting
  • Novartis Investigative Site
    CABA, C1181ACH, Argentina
    Recruiting
  • Novartis Investigative Site
    Hamilton, Ontario L8L 3C3, Canada
    Recruiting
  • Novartis Investigative Site
    Québec, Quebec G1W 4R4, Canada
    Recruiting
  • Novartis Investigative Site
    Kitakyushu, Fukuoka 8078556, Japan
    Recruiting
  • Novartis Investigative Site
    Yokohama, Kanagawa 2400013, Japan
    Recruiting
  • Novartis Investigative Site
    Kumamoto, Kumamoto 8620950, Japan
    Recruiting
  • Novartis Investigative Site
    Habikino, Osaka 5838588, Japan
    Recruiting
  • Novartis Investigative Site
    Sakai, Osaka 5938324, Japan
    Recruiting
  • Novartis Investigative Site
    Tachikawa, Tokyo 1900023, Japan
    Recruiting
  • Novartis Investigative Site
    Ansan, Gyeonggi-do 15355, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, 03722, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, 07804, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2029, 39 months after the start.

Of 42 industry-sponsored phase 3 interventional studies under Pruritus, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's planned 39 months is above that.

Counting every sponsor, half of 48 studies reached it within 19 months; a quarter within 12 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 13, 2026
StartActual
Aug 24, 2026
Primary completionEst.
Dec 19, 2029
CompletionEst.
Apr 15, 2030
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
19 sites added — first sites in Canada, South Korea and Argentina
Show 19 added (6 United States, 5 Japan, 3 South Korea, 3 Argentina, 2 Canada)
  • Driven Research · Miami, United States
  • Equity Medical · The Bronx, United States
  • National Allergy and Asthma Research LLS · North Charleston, United States
  • Novartis Investigative Site · Hamilton, Canada
  • Novartis Investigative Site · Québec, Canada
  • Novartis Investigative Site · Sakai, Japan
  • Novartis Investigative Site · Ansan, South Korea
  • Novartis Investigative Site · Seoul, South Korea
  • Southern IN Clinical Trials · New Albany, United States
  • Novartis Investigative Site · Rosario, Argentina
  • Novartis Investigative Site · Yokohama, Japan
  • Novartis Investigative Site · Seoul, South Korea
  • Aller Vie Health-Cullman · Cullman, United States
  • Allergy and Clinical Immunology Associates · Pittsburgh, United States
  • Novartis Investigative Site · Caba, Argentina
  • Novartis Investigative Site · CABA, Argentina
  • Novartis Investigative Site · Kitakyushu, Japan
  • Novartis Investigative Site · Kumamoto, Japan
  • Novartis Investigative Site · Habikino, Japan
across 3 updates, Sep 28, 2026 – Nov 9, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Austin Inst for Clinical Research · Pflugerville, United StatesContact •••2545→•••2545
  • Dawes Fretzin Clinical Rea Group · Indianapolis, United StatesContact j•••@ecommunity.com · •••0102→j•••@ecommunity.com · •••0102
across 2 updates, Sep 28, 2026 – Oct 13, 2026
Show all 3 updates
  1. Nov 9, 2026
    7 sites added
    Show 7 added (3 Japan, 2 United States, 2 Argentina)
    • Aller Vie Health-Cullman · Cullman, United States
    • Allergy and Clinical Immunology Associates · Pittsburgh, United States
    • Novartis Investigative Site · Caba, Argentina
    • Novartis Investigative Site · CABA, Argentina
    • Novartis Investigative Site · Kitakyushu, Japan
    • Novartis Investigative Site · Kumamoto, Japan
    • Novartis Investigative Site · Habikino, Japan
    + 1 other change: verification date
  2. Oct 13, 2026
    4 sites added — first site in Argentina
    Show 4 added (1 United States, 1 Argentina, 1 Japan, 1 South Korea)
    • Southern IN Clinical Trials · New Albany, United States
    • Novartis Investigative Site · Rosario, Argentina
    • Novartis Investigative Site · Yokohama, Japan
    • Novartis Investigative Site · Seoul, South Korea
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Dawes Fretzin Clinical Rea Group · Indianapolis, United StatesContact j•••@ecommunity.com · •••0102→j•••@ecommunity.com · •••0102
    + 1 other change: verification date
  3. Sep 28, 2026
    8 sites added — first sites in Canada and South Korea
    Show 8 added (3 United States, 2 Canada, 2 South Korea, 1 Japan)
    • Driven Research · Miami, United States
    • Equity Medical · The Bronx, United States
    • National Allergy and Asthma Research LLS · North Charleston, United States
    • Novartis Investigative Site · Hamilton, Canada
    • Novartis Investigative Site · Québec, Canada
    • Novartis Investigative Site · Sakai, Japan
    • Novartis Investigative Site · Ansan, South Korea
    • Novartis Investigative Site · Seoul, South Korea
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Austin Inst for Clinical Research · Pflugerville, United StatesContact •••2545→•••2545
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07700056
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Aug 24, 2026
Primary completion
Dec 19, 2029 (estimated)
Completion
Apr 15, 2030 (estimated)
Last update
Nov 9, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion